How much funding has Orexigen Therapeutics raised?

Orexigen Therapeutics has raised $30.0M in total funding, most recently a Series C round.

When was Orexigen Therapeutics founded?

Orexigen Therapeutics was founded in 2004.

Where is Orexigen Therapeutics headquartered?

Orexigen Therapeutics is headquartered in USA, California, United States.

What industry is Orexigen Therapeutics in?

Orexigen Therapeutics operates in Biotech.

How many employees does Orexigen Therapeutics have?

Orexigen Therapeutics has 51-200 employees.

Orexigen Therapeutics

Q: Who are Orexigen Therapeutics's investors?

Orexigen Therapeutics's investors include New Enterprise Associates, MPM BioEquities, Wasatch Ventures.

Closed

USA, United States · Founded 2004 · $30.0M raised

Biotech

Headquarters: USA, California
Employees: 51–200
Founded: 2004
Business Model: B2B

Website: orexigen.com
Total Funding: $30.0M
Last Round: $30.0M Series CNov 2006
Rounds: 2

About

Orexigen Therapeutics was a La Jolla, California-based biopharmaceutical company focused on treatments for obesity. The company developed Contrave (naltrexone/bupropion extended-release), an FDA-approved prescription weight-loss medication. Orexigen filed for Chapter 11 bankruptcy in March 2018 and its assets were acquired by Nalpropion Pharmaceuticals.

Summary

Orexigen Therapeutics is a Biotech company based in USA, United States, founded in 2004. It has raised $30.0M in total across 2 rounds, most recently a $30.0M Series C round in Nov 2006. Investors include New Enterprise Associates, MPM BioEquities and Wasatch Ventures.